

Attorney Docket No. 0727-1003

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

AL-MAHMOOD, Salman

Confirm. No. 6845

Serial No. 10/735,512

Group Art Unit 1635

File December 12, 2003

Examiner Sean McGARRY

Patent No. 7,417,033

Issue Date August 26, 2008

ANTISENSE OLIGONUCLEOTIDES CAPABLE OF INHIBITING THE FORMATION  
OF CAPILLARY TUBES BY ENDOTHELIAL CELLS AND METHODS OF TREATING  
OPHTHALMIC AND DERMATOLOGICAL DISEASES

**REVOCATION AND POWER OF ATTORNEY**  
**AND 37 CFR §3.73(b) STATEMENT**

**MAIL STOP**

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Revoking all previous powers of attorney, **Gene Signal International SA**, hereby appoints the registered patent practitioners associated with **Customer No. 00466**, whose address is:

c/o YOUNG & THOMPSON  
209 Madison Street, Suite 500  
Alexandria, VA 22314

as attorneys to prosecute this patent and to transact all business in the Patent and Trademark Office in connection therewith.

**Gene Signal International SA** is assignee of the above-identified patent by virtue of a chain of title from the inventor, of the patent identified above, to the current assignee as shown below:

1. From: Salman AL-MAHMOOD  
To: Gene Signal

The document was recorded in the Patent and Trademark

Patent No. 7,417,033

Office on April 21, 2004, at Reel 015236, Frame 0421, or for which a copy thereof is attached.

2. From: Gene Signal

To: Gene Signal International

The document was recorded in the Patent and Trademark Office on March 30, 2006, at Reel 017390, Frame 0335, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully Submitted,

Gene Signal International SA

Date: 27/11/2009

Name: Eric Viaud

Title: CEO

Signature: 